Condition

Hyperglycaemia (Diabetic)

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 17 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17
Recruiting4
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

17 shown
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular DiseasesNCT07588256 · 2026-02-05
RECRUITING
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 DiabetesNCT07167693 · 2025-12-19
RECRUITING
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone ImplantNCT06984822 · 2025-08-01
RECRUITING
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)NCT03087032 · 2019-01-10
RECRUITING
The BRIGHT Study (Device Name: HALO System)NCT07745998 · 2026-12-01
NOT_YET_RECRUITING
Validation of Remote Photoplethysmography for Non-Invasive Estimation of Blood Glucose and HbA1cNCT07502690 · 2026-03-23
NOT_YET_RECRUITING
Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in BogotáNCT07748559 · 2024-10-22
COMPLETED
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DMNCT07014735 · 2023-04-13
TERMINATED
To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body CompositionNCT07626775 · 2023-01-01
COMPLETED
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic SubjectsNCT05597605 · 2022-09-21
COMPLETED
The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic PatientsNCT03708887 · 2020-10-10
COMPLETED
Hypoglycaemia and Cardiac Arrhythmias in Type 1 DiabetesNCT04011683 · 2018-12-01
COMPLETED
Peripheral Nerve Blocks for Above-the-knee AmputationsNCT03404180 · 2018-02-09
COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes MellitusNCT03414892 · 2018-01-03
COMPLETED
Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 DiabetesNCT03356457 · 2017-11-30
COMPLETED
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin HydrochlorideNCT03171623 · 2017-04-05
COMPLETED
Microclinic Social Network Behavioral Health Trial in JordanNCT01818674 · 2012-01-01
COMPLETED

Common interventions

Trial status mix

COMPLETED10
RECRUITING4
NOT_YET_RECRUITING2
TERMINATED1

Phase mix

NA8
PHASE13
PHASE42
EARLY_PHASE11
PHASE21
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.